Ipsapirone in the treatment of bulimia nervosa: an open pilot study.
Seventeen women who met the criteria for bulimia nervosa (DSM-III-R) were treated for 4 weeks in an open trial with ipsapirone, a partial 5-HT1A agonist. Bulimic symptoms diminished in 66.6% of the patients after only 1 week of treatment, 93.3% showed a reduction of more than 50% of weekly binge eating attacks after 4 weeks. The mean frequency of binges was reduced by 81% at endpoint. Ipsapirone was well tolerated.
Geretsegger
C
C
Acute Treatment Services, Salzburg State Hospital, Austria.
Greimel
K V
KV
Roed
I S
IS
Hesselink
J M
JM
D000328:Adult; D002032:Bulimia / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D010555:Personality Inventory; D010865:Pilot Projects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D011743:Pyrimidines; D017366:Serotonin Receptor Agonists; C043077:ipsapirone